



AUBURN UNIVERSITY
Harrison College of Pharmacy

HARRISON COLLEGE OF PHARMACY




CONTINUING
EDUCATION

Recorded Buprenorphine for Opioid Use Disorder: Clinical Effectiveness, Safety, and Access

Dr. Luke Engeriser

Recorded Webinar



PROGRAM OVERVIEW

Buprenorphine is a cornerstone medication for the treatment of opioid use disorder (OUD) and plays a critical role in reducing overdose risk and improving treatment retention. This session provides an overview of buprenorphine's pharmacology, effectiveness, and role within evidence-based OUD treatment. Participants will review initiation strategies, maintenance therapy, and considerations for special populations. The session will also explore safety issues, diversion concerns, stigma, regulatory changes, and interdisciplinary collaboration to improve patient access and outcomes.

The registration fee for this program is Free

Following registration, participants will have access to course instructions, presentations, recorded webinar, program evaluation, CE certificates and credits, etc. **This program is approved for 1 ACPE Contact Hours, .1 CEUs.** Once credit is awarded, transcripts will be available online within 24 hours on the learner's CPE Monitor profile at <http://nabp.pharmacy>

The Office of Professional Affairs strongly encourages each participant to check their profile online within 60 days of attendance to ensure credit has been awarded properly. ACPE will not accept CE submissions after 60 days from the live seminar date.

This program is not sponsored by an external organization and no commercial support has been received for this activity.

TARGET AUDIENCE

This application-based course is intended for Pharmacists (ACPE), Pharmacy Technicians (ACPE), Physicians (ACCME), Physician Assistants (ACCME), Nurse Practitioners (ABN), Dentists (AL board approval), Nurses (ABN), Social Workers (ABSWE).

LEARNING OBJECTIVES

At the conclusion of this session, participants will be able to:

- Describe the mechanism of action and therapeutic benefits of buprenorphine in the treatment of opioid use disorder.
- Identify best practices for initiating and maintaining buprenorphine therapy in diverse clinical settings.
- Recognize safety considerations, contraindications, and strategies to reduce misuse and diversion.
- Discuss regulatory requirements, stigma-related barriers, and system-level factors affecting access to buprenorphine treatment

ACTIVITY COMPLETION REQUIREMENTS

Participants are encouraged to secure a direct connection for all webinar programming. Please arrange for access to a computer with stable internet connection and Zoom capabilities. This program will be conducted via Zoom and includes interactive components.

If you're a new participant, we have a quick start guide here: <https://aub.ie/zoomquickstart>.

TECHNOLOGY REQUIREMENTS

To complete the steps for CE credit, each attendee will be required to access and review program materials located within the online course, view the recorded webinar, complete the quiz and program evaluation within the online course, and claim credit within the course. Please contact hcopce@auburn.edu if you have any questions or needs related to this online CE program.

PROGRAM FACULTY

Dr. Engeriser attended medical school at Northwestern University and completed psychiatry residency training at Tripler Army Medical Center in Honolulu. Dr. Engeriser served an additional three years in the Army at Fort Benning, Georgia, where he held the position of Chief, Department of Behavioral Health. After separating from the Army, Dr. Engeriser was Medical Director of Mid-Coast Mental Health Center/PenBay Psychiatry in Rockland, Maine. Prior to attending medical school, he completed a Master of Arts in Divinity at the University of Chicago and worked as a teacher of English at the Teacher Training College in Torun, Poland. Dr. Engeriser is a Past President of the Alabama Psychiatric Physicians Association, and he is currently President of the Alabama Society of Addiction Medicine. He is a Distinguished Fellow of the American Psychiatric Association and American Society of Addiction Medicine. He is currently the Deputy Chief Medical Officer for AltaPointe Health and is the Program Director for the Psychiatry Residency and Addiction Medicine Fellowship at the University of South Alabama.

ACCREDITATION INFORMATION

The Auburn University Harrison College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider for continuing pharmacy education; credits are recognized nationwide. The Universal Activity Number for this knowledge-based program is **0001-9999-26-005-H08-P** and is intended for Pharmacists (ACPE), Pharmacist Technicians (ACPE), Physicians (ACCME), Physician Assistants (ACCME), Nurse Practitioners (ABN), Nurses (ABN), Dentists (AL board approval), and Social Workers (ABSWE). The initial release date for this program is February 20, 2026, and the intended expiration date is February 20, 2029.

ABN - Auburn University Harrison College of Pharmacy is a Board-approved provider of continuing nursing education in Alabama by the Alabama Board of Nursing. Provider Number: ABNP1515.

ABSWE - Auburn University Harrison College of Pharmacy is a Board-approved provider of continuing education for social workers by the Alabama Board of Social Work Examiners. Provider Number: 0643.

ACCME - The Huntsville Hospital designates this live activity for a maximum of *1.0 AMA PRA Category 1 Credit(s)TM*. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Medical Association of the State of Alabama through the joint providership of the Huntsville Hospital and Auburn University Harrison College of Pharmacy. The Huntsville Hospital is accredited by the Medical Association of the State of Alabama to provide continuing medical education for physicians.

Disclosures: There is no commercial support being received for this program. Dr. Engeriser and others in control of content have no actual or potential conflict of interest in relation to this program. No individuals in a position to control content for this activity have any relevant financial relationships to declare.

FACULTY DISCLOSURES

Programming in with AUHCOP is in any way involved, whether as sole provider or joint-providership, shall exhibit fair content balance, providing the audience with information of multiple perspectives from which to form a professional opinion. In addition, the fair balance will assure that information provided does not discuss a commercial product. Brand names of all products included in the content may be mentioned for identification purposes only. Presenters in any continuing education offering will acknowledge and disclose any affiliation with the provider and such information will be made available to the audience.

Faculty disclosures will also be included on an introductory slide during the presentation.

POST-GRADUATE EDUCATION ADVISORY COMMITTEE

Spencer Durham, Pharm.D., BCPS, BCIDP
Associate Clinical Professor, Director of Professional Affairs
Harrison College of Pharmacy

Amy Carbajal, MPA
Chief Operations Officer, Harrison College of Pharmacy

Natalie Hohmann, Pharm.D., Ph.D.
Associate Professor, Drug Discovery and Development, Harrison College of Pharmacy

Haley Phillippe, Pharm.D., FASCP, BCPS, BCGP
Clinical Professor, Pharmacy Practice, Harrison College of Pharmacy

Abby Bell, BSN, RNC-OB
Clinical Placement and Nurse Apprenticeship Coordinator, AU College of Nursing

Brianna Foster
Program Administrator, Alumni Affairs, Harrison College of Pharmacy

Tanja Redd, MBA, Ph.D.
Program Administrator, Professional Affairs, Harrison College of Pharmacy

Members of the Post-Graduate Education Advisory Committee have completed a conflict-of-interest disclosure form and have no actual or potential conflicts of interest in relation to this program.